Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bayer HealthCare to present cancer drug data at ESMO 2014

Bayer HealthCare to present cancer drug data at ESMO 2014

24th September 2014

Bayer HealthCare has announced that it will be presenting data on a number of its cancer therapies at the European Society for Medical Oncology (ESMO) Congress in Madrid.

The conference will take place from September 26th to 30th and will see the firm share its latest research findings on oncology therapies such as Stivarga, Nexavar and Xofigo.

Among the presentations will be the announcement of findings from the phase III CONCUR trial, which evaluated the efficacy and safety of Stivarga among Asian patients with previously treated metastatic colorectal cancer.

Dr Joerg Moeller, member of the Bayer HealthCare executive committee and head of global development, said: "Bayer's presence at this global conference demonstrates our commitment and progress in exploring new treatment options for cancer patients around the world across various tumour types through both our robust portfolio and pipeline."

This comes after the firm announced earlier this month that it has allied with Orion to launch a phase III trial assessing ODM-201, an investigational novel oral androgen receptor inhibitor, among patients with prostate cancer.ADNFCR-8000103-ID-801750314-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.